[HTML][HTML] Future newborns with opioid-induced Neonatal Abstinence Syndrome (NAS) could be assessed with the Genetic Addiction Risk Severity (GARS) test and …
M Ceccanti, K Blum, A Bowirrat, CA Dennen… - Journal of Personalized …, 2022 - mdpi.com
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat… - Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat… - Journal of …, 2022 - search.proquest.com
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
[PDF][PDF] Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat, CA Dennen… - J. Pers. Med, 2022 - academia.edu
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat, CA Dennen… - Journal of …, 2022 - europepmc.org
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat… - Journal of …, 2022 - search.ebscohost.com
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future newborns with opioid-induced neonatal abstinence syndrome (NAS) could be assessed with the genetic addiction risk severity (GARS) test and potentially …
M Ceccanti, MS Gold - 2022 - digitalcommons.wustl.edu
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
[HTML][HTML] Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat… - Journal of …, 2022 - ncbi.nlm.nih.gov
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
[PDF][PDF] Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat, CA Dennen… - J. Pers …, 2022 - pdfs.semanticscholar.org
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and …
M Ceccanti, K Blum, A Bowirrat… - Journal of …, 2022 - scholars.uthscsa.edu
In this nonsystematic review and opinion, including articles primarily selected from PubMed,
we examine the pharmacological and nonpharmacological treatments of neonatal …
we examine the pharmacological and nonpharmacological treatments of neonatal …